Impact of the Addition of Baricitinib to Standard of Care Including Tocilizumab and Corticosteroids on Mortality and Safety in Severe COVID-19

Impact of the Addition of Baricitinib to Standard of Care Including Tocilizumab and Corticosteroids on Mortality and Safety in Severe COVID-19

Background: Baricitinib is a Janus kinase (JAK) inhibitor with a broader anti-inflammatory activity than tocilizumab and an antiviral potential although no head-to-head trials are available. The benefits of adding baricitinib to patients with COVID-19 experiencing clinical progression despite the st...

Full description

Bibliographic Details
Main Authors: Mar Masiá, Sergio Padilla, José Alberto García, Javier García-Abellán, Andrés Navarro, Lucía Guillén, Guillermo Telenti, Paula Mascarell, Ángela Botella, Félix Gutiérrez
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-11-01
Series:Frontiers in Medicine
Subjects:
baricitinib
mortality
thrombosis
coinfection
COVID-19
SARS-CoV-2
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2021.749657/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2021.749657/full

Similar Items